Denise Scots-Knight - Jun 21, 2024 Form 4 Insider Report for Mereo BioPharma Group plc (MREO)

Role
Chief Executive Officer, Director
Signature
/s/ Christine Fox, by power of attorney
Stock symbol
MREO
Transactions as of
Jun 21, 2024
Transactions value $
$0
Form type
4
Date filed
6/25/2024, 06:15 PM
Previous filing
Jan 26, 2024
Next filing
Jun 27, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MREO American Depositary Shares representing Ordinary Shares Options Exercise $0 +282K +50.34% $0.00 843K Jun 21, 2024 Direct F1, F2, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MREO Performance Based Restricted Stock Unit Options Exercise $0 +282K $0.00 188K Jun 21, 2024 American Depository Shares 282K $0.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
F2 Represents performance-based restricted stock unit ("PSU") earned under the issuer's 2019 Employee Incentive Plan (the "Plan") that vested on June 21, 2024 based on satisfaction of ADS price threshold values over a two year performance period (expiring on January 1, 2025).
F3 Reporting Person also beneficially owns 4 ordinary shares, nominal value of GBP 0.003 per ordinary share, of the Issuer.
F4 Includes 1,200 ADSs jointly owned by Reporting person and her spouse.